GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (FRA:5LB) » Definitions » 5-Year RORE %

BioVaxys Technology (FRA:5LB) 5-Year RORE % : 4.05% (As of Jul. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioVaxys Technology 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. BioVaxys Technology's 5-Year RORE % for the quarter that ended in Jul. 2024 was 4.05%.

The industry rank for BioVaxys Technology's 5-Year RORE % or its related term are showing as below:

FRA:5LB's 5-Year RORE % is ranked better than
66.64% of 1106 companies
in the Biotechnology industry
Industry Median: -7.6 vs FRA:5LB: 4.05

BioVaxys Technology 5-Year RORE % Historical Data

The historical data trend for BioVaxys Technology's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology 5-Year RORE % Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
5-Year RORE %
Get a 7-Day Free Trial - - - - 15.38

BioVaxys Technology Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.28 15.38 12.50 10.19 4.05

Competitive Comparison of BioVaxys Technology's 5-Year RORE %

For the Biotechnology subindustry, BioVaxys Technology's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVaxys Technology's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's 5-Year RORE % falls into.



BioVaxys Technology 5-Year RORE % Calculation

BioVaxys Technology's 5-Year RORE % for the quarter that ended in Jul. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.021--0.012 )/( -0.222-0 )
=-0.009/-0.222
=4.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jul. 2024 and 5-year before.


BioVaxys Technology  (FRA:5LB) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


BioVaxys Technology 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

BioVaxys Technology Headlines

No Headlines